The tight complexes FKBP12 forms
with immunosuppressive drugs,
such as FK506 and rapamycin, are frequently used as models for developing
approaches to structure-based drug design. Although the interfaces
between FKBP12 and these ligands are well-defined structurally and
are almost identical in the X-ray crystallographic structures of various
complexes, our nuclear magnetic resonance studies have revealed the
existence of substantial large-amplitude motions in the FKBP12–ligand
interfaces that depend on the nature of the ligand. We have monitored
these motions by measuring the rates of Tyr and Phe aromatic ring
flips, and hydroxyl proton exchange for residues clustered within
the FKBP12–ligand interface. The results show that the rates
of hydroxyl proton exchange and ring flipping for Tyr26 are much slower
in the FK506 complex than in the rapamycin complex, whereas the rates
of ring flipping for Phe48 and Phe99 are significantly faster in the
FK506 complex than in the rapamycin complex. The apparent rate differences
observed for the interfacial aromatic residues in the two complexes
confirm that these dynamic processes occur without ligand dissociation.
We tentatively attribute the differential interface dynamics for these
complexes to a single hydrogen bond between the ζ-hydrogen of
Phe46 and the C32 carbonyl oxygen of rapamycin, which is not present
in the KF506 complex. This newly identified Phe46 ζ-hydrogen
bond in the rapamycin complex imposes motional restriction on the
surrounding hydrophobic cluster and subsequently regulates the dynamics
within the protein–ligand interface. Such information concerning
large-amplitude dynamics at drug–target interfaces has the
potential to provide novel clues for drug design.